1.5 versus 3 Tesla structural MRI in patients with focal epilepsy.

Epileptic Disord

Hotchkiss Brain Institute, University of Calgary, Seaman Family MR Research Centre, University of Calgary, Department of Clinical Neurosciences, University of Calgary, Department of Radiology, University of Calgary, Canada.

Published: April 2022

Objective: Structural MRI is a critical component in the pre-surgical investigation of epilepsy, as identifying an epileptogenic lesion increases the chance of post-surgical seizure freedom. In general practice, 1.5T and 3T MRI scans are still the mainstream in most epilepsy centres, particularly in resource-poor countries. When 1.5T MRI is non-lesional, a repeat scan is often performed as a higher-field structural scan, usually 3T. However, it is not known whether scanning at 3T increases diagnostic yield in patients with focal epilepsy. We sought to compare lesion detection and other features of 1.5T and 3T MRI acquired in the same patients with epilepsy.

Methods: MRI scans (1.5T and 3T) from 100 patients were presented in a blinded, randomized order to two neuroradiologists. The presence, location, and number of potentially epileptogenic lesions were compared. In addition, tissue contrast and the presence of motion/technical artifacts were compared using a 4-point subjective scale.

Results: Both the qualitative tissue contrast and motion/technical artifacts were improved at 3T. However, this did not result in statistically significant improvement in lesion detection. Qualitatively, five patients had subtle lesions seen only at 3T. However, minor differences in image acquisition parameters between 1.5T and 3T scans in these cases may have resulted in greater lesion visibility at 3T in four patients. Based on a general linear model analysis, the presence of a focal abnormality on EEG was predictive of the presence of a lesion at 1.5T and 3T.

Significance: Repeat MRI scanning of patients with focal epilepsy at 3T using similar scan protocols does not significantly increase diagnostic yield over scanning at 1.5T; the increased signal-to-noise ratio can potentially be better allocated for novel scan sequences in order to provide more clinical value.

Download full-text PDF

Source
http://dx.doi.org/10.1684/epd.2021.1384DOI Listing

Publication Analysis

Top Keywords

patients focal
12
focal epilepsy
12
15t mri
12
structural mri
8
mri scans
8
diagnostic yield
8
lesion detection
8
tissue contrast
8
motion/technical artifacts
8
mri
7

Similar Publications

A 5 yr old chihuahua presented to our clinic with a complaint of decreased activity and focal seizures. Based on the findings of MRI and computed tomography, a primary brain tumor originating from the right frontal lobe region was suspected. Surgical resection was performed, and a diagnosis of histiocytic sarcoma was made via histopathological examination and immunohistochemical staining.

View Article and Find Full Text PDF

Background: The diagnosis of intracranial extraosseous Ewing's sarcoma (EES) poses challenges due to the absence of specific clinical and imaging features prior to surgery. It is crucial to differentiate the tumor from other small round cell malignancies postoperatively.

Observations: A 7-year-old patient was admitted to the authors' hospital due to the in situ recurrence of a posterior fossa tumor more than 1 month after the initial surgery for headache.

View Article and Find Full Text PDF

MYCN-amplified spinal ependymomas: a rare aggressive subtype. Illustrative cases.

J Neurosurg Case Lessons

January 2025

Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.

Background: Spinal ependymomas are typically slow-growing tumors with a favorable prognosis. Recently, a new aggressive subtype has emerged with its own distinct histopathological and molecular features characterized by MYCN amplification. However, this subtype of spinal ependymoma is rare, and studies on its imaging characteristics are limited.

View Article and Find Full Text PDF

Reply to: Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer?

J Clin Oncol

January 2025

Aaron J. Scott, MD, University of Arizona Cancer Center, Tucson, AZ; Erin B. Kennedy, MHSc, American Society of Clinical Oncology, Alexandria, VA; and Sepideh Gholami, MD, MAS, Northwell Health, New Hyde Park, NY.

View Article and Find Full Text PDF

Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer?

J Clin Oncol

January 2025

Mahsoem Ali, BSc; and Lenka N.C. Boyd, MD, Amsterdam UMC, Location Vrije Universiteit, Department of Surgery, Amsterdam, the Netherlands, Amsterdam UMC, Location Vrije Universiteit, Department of Medical Oncology, Lab of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Elisa Giovannetti, MD PhD, Amsterdam UMC, Location Vrije Universiteit, Department of Medical Oncology, Lab of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands, Cancer Pharmacology Lab, AIRC Start-Up Unit, Fondazione Pisa per la Scienza, Pisa, Italy; and Geert Kazemier, MD, PhD, Amsterdam UMC, Location Vrije Universiteit, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!